Bayer AG Halts Study of Hemophilia Therapy BAY 86-6150 Due to Safety Concerns

Published: May 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

Help employers find you! Check out all the jobs and post your resume.

Back to news